TECH
FY2026 Q3 · Calendar Q2 2026
Bio-Techne Corporation
Bio-Techne's Q3 FY2026 results showed a 2% organic revenue decline, though underlying growth was 2% after excluding cell-therapy and OEM timing headwinds. Both EPS ($0.53 vs. $0.55 estimated) and revenue ($311.4M vs. $316.1M estimated) missed consensus. The market reacted sharply, with the stock falling 17.7% on an abnormal basis, though it partially recovered with a 12.2% subsequent drift. The core thesis hinges on growth platforms — COMET spatial biology (>65% growth, record backlog), Ella proteomics (CE-IVD marking achieved), and GMP cell-therapy reagents (~50% YoY growth ex-timing) — offsetting near-term softness in emerging biotech spending and customer timing issues. Management maintained guidance but shifted the acceleration narrative to FY2027, tempering near-term expectations.
EPS surprise-3.6%
Market move-16.4%
